Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

NCT07348965 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)
Leptomeningeal Metastasis
Furmonertinib
EGFR Activating Mutation

Interventions

DRUG: Furmonertinib 320mg qod po
DRUG: Furmonertinib 160mg qd po

Sponsor

Guangzhou University of Traditional Chinese Medicine